WASHINGTON, Jan. 12, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) submitted a comment letter (here) on January 5, 2024, regarding the FDA’s recently announced policy—by way of a draft guidance document—that substantially restricts drug manufacturers’ ability to…
Vanda Pharmaceuticals Comments on FDA’s Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
This post was originally published on this site